Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...

February 3, 2026 • Journalist Gabriel Sherman has covered the Murdoch family for nearly two decades. In his new book, Bonfire of the Murdochs, he chronicles the protracted public battle for control ...